Verve Therapeutics (NASDAQ:VERV) Full Year 2024 Results

Key Financial Results

• Revenue: US$32.3m (up 175% from FY 2023).
• Net loss: US$198.7m (flat on FY 2023).
• US$2.35 loss per share (improved from US$3.12 loss in FY 2023).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Verve Therapeutics Revenues and Earnings Beat Expectations

Revenue exceeded analyst estimates by 36%. Earnings per share (EPS) also surpassed analyst estimates by 6.0%.

Looking ahead, revenue is expected to decline by 9.0% p.a. on average during the next 3 years, while revenues in the Biotechs industry in the US are expected to grow by 20%.

Performance of the American Biotechs industry.

The company's shares are down 21% from a week ago.

Risk Analysis

Before we wrap up, we've discovered 3 warning signs for Verve Therapeutics (1 is concerning!) that you should be aware of.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.